logo-loader
viewAC Immune

Alzheimer's focused AC Immune has multiple shots on goal, says Jefferies, which targets $25

Jefferies targets a punchy $25 for the shares, well over three times' the current price of at $7.30

shutterstock_118491940_5991b0e277a27.jpg
Last week the group confirmed that all key pipeline programmes were on-track

Alzheimer's focused biotech AC Immune Ltd (NASDAQ:ACIU) is undervalued in the light of its multiple shots on goal for treating the brain disease, says US broker Jefferies, which rates shares a 'buy'.

Jefferies targets a punchy $25 for the shares, well over three times' the current price of at $7.30 - up 2.53% on the day.

Its candidate Crenezumab underpins the broker's valuatrion of the group, which is partnered with Genentech in a Phase III trial with data expected in the second half of 2020. The broker estimates US$4.4bn world wide peak sales for the drug by 2028 estimates for $16 a share net present value (NPV).

Analyst Peter Welford notes that ACIU has three other Phase Ib-IIa products for a pipeline providing a multitude of catalysts by 2018.

He reckons the biotech's below $300mln enterprise value (EV) substantially undervalues the group.

Last week the group confirmed that all key pipeline programmes were on-track, he adds.

"We still expect a further update on anti-Abeta vaccine ACI-24 by YE, with the 4th dose cohort ongoing in Phase I/IIa."

Welford adds: "We forecast cash to be adequate for burn well into 2019E, by which time a significant number of catalysts could crystallise value."

Quick facts: AC Immune

Price: 8.36 USD

NASDAQ:ACIU
Market: NASDAQ
Market Cap: $563.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medicenna Therapeutics completes Phase 2B study on cancer drug mdna55

Medicenna Therapeutics (TSE: MDNA) CFO Elizabeth Williams joined Steve Darling from Proactive Vancouver at LD MIcrocap Conference in Vancouver with news about their lead drug mdma55. Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization...

8 hours, 46 minutes ago

2 min read